BNP Paribas Financial Markets Grows Stake in Establishment Labs Holdings Inc. $ESTA

BNP Paribas Financial Markets raised its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 296.8% during the fourth quarter, Holdings Channel reports. The fund owned 196,120 shares of the company’s stock after buying an additional 146,697 shares during the period. BNP Paribas Financial Markets’ holdings in Establishment Labs were worth $14,293,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC boosted its stake in Establishment Labs by 11.1% in the third quarter. Nantahala Capital Management LLC now owns 1,973,492 shares of the company’s stock valued at $80,893,000 after acquiring an additional 197,962 shares during the last quarter. Bamco Inc. NY lifted its stake in shares of Establishment Labs by 30.2% during the 3rd quarter. Bamco Inc. NY now owns 1,181,824 shares of the company’s stock valued at $48,443,000 after buying an additional 274,287 shares in the last quarter. Tyro Capital Management LLC lifted its stake in shares of Establishment Labs by 1.0% during the 3rd quarter. Tyro Capital Management LLC now owns 1,077,456 shares of the company’s stock valued at $44,165,000 after buying an additional 10,735 shares in the last quarter. William Blair Investment Management LLC lifted its stake in shares of Establishment Labs by 17.6% during the 3rd quarter. William Blair Investment Management LLC now owns 1,017,543 shares of the company’s stock valued at $41,709,000 after buying an additional 152,299 shares in the last quarter. Finally, Mudita Advisors LLP lifted its stake in shares of Establishment Labs by 14.3% during the 3rd quarter. Mudita Advisors LLP now owns 686,764 shares of the company’s stock valued at $28,150,000 after buying an additional 86,100 shares in the last quarter. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

Establishment Labs Price Performance

Shares of NASDAQ:ESTA opened at $74.31 on Monday. The company’s fifty day moving average price is $66.49 and its 200-day moving average price is $68.70. The firm has a market capitalization of $2.19 billion, a price-to-earnings ratio of -49.87 and a beta of 1.11. Establishment Labs Holdings Inc. has a one year low of $33.35 and a one year high of $83.31. The company has a debt-to-equity ratio of 16.82, a current ratio of 2.96 and a quick ratio of 1.91.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). The company had revenue of $59.88 million during the quarter, compared to the consensus estimate of $57.40 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.Establishment Labs’s quarterly revenue was up 44.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.70) EPS. On average, equities research analysts anticipate that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current fiscal year.

Insider Activity at Establishment Labs

In related news, Director Quiros Juan Jose Chacon sold 105,000 shares of the stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the transaction, the director owned 927,504 shares of the company’s stock, valued at approximately $69,952,351.68. This trade represents a 10.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last 90 days, insiders have sold 330,000 shares of company stock valued at $22,854,538. 9.99% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

ESTA has been the topic of several recent analyst reports. Wall Street Zen cut shares of Establishment Labs from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research note on Friday, March 27th. Citigroup reiterated a “neutral” rating on shares of Establishment Labs in a research note on Wednesday, May 6th. Canaccord Genuity Group increased their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Finally, Stephens increased their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.14.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.